CYAD Celyad SA

10.19
-0.01  -0%
Previous Close 10.2
Open 10.19
Price To Book 2.68
Market Cap 121,692,485
Shares 11,942,344
Volume 2,433
Short Ratio
Av. Daily Volume 36,164

NewsSee all news

  1. Celyad Announces Closing of $20 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  2. Horizon Discovery Group plc: Results for the Six Months Ended 30 June 2019

    RNS Horizon Discovery Group plcResults for the Six Months Ended 30 June 2019 Cambridge, UK, 16 September 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global

  3. Celyad Announces Pricing of $20.0 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  4. Celyad Announces Launch of Proposed Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies,

  5. Be The Match BioTherapies® and Celyad Announce Collaboration to Advance Development of Allogeneic CAR-T Therapies

    Alliance will support the clinical progression of Celyad's non-gene edited allogeneic CAR-T candidates Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data did not meet primary endpoint
C-Cure - Chart 1 trial
Chronic Heart Failure secondary to ischemic cardiomyopathy
Phase 1 data from Cohort 11 (schedule optimization) due by end of 2019.
CYAD-01 - THINK
Various cancers - solid and hematologic cancers
Phase 1 additional data due year-end 2019.
CYAD-101 - alloSHRINK
Colorectal cancer
Phase 1 data to presented at ESMO July 2019 noted 1/9 partial responses, 6/9 stable disease.
CYAD-01 and FOLFOX - SHRINK
Colorectal cancer
Phase 1 Cohort 3 data due year-end 2019.
CYAD-01 and chemotherapy (DEPLETHINK)
AML or myelodysplastic syndrome (MDS)
Phase 1 trial to commence early 2020 with data due mid-2020.
CYAD-02
Relapsed/refractory Acute myeloid leukemia (AML) and Myelodysplastic Syndrome (MDS)

Latest News

  1. Celyad Announces Closing of $20 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  2. Horizon Discovery Group plc: Results for the Six Months Ended 30 June 2019

    RNS Horizon Discovery Group plcResults for the Six Months Ended 30 June 2019 Cambridge, UK, 16 September 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global

  3. Celyad Announces Pricing of $20.0 Million Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today

  4. Celyad Announces Launch of Proposed Global Offering

    MONT-SAINT-GUIBERT, Belgium, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies,

  5. Be The Match BioTherapies® and Celyad Announce Collaboration to Advance Development of Allogeneic CAR-T Therapies

    Alliance will support the clinical progression of Celyad's non-gene edited allogeneic CAR-T candidates Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell

  6. Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

    MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  7. Celyad to Participate in Upcoming September 2019 Conferences

    MONT-SAINT-GUIBERT, Belgium, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies,

  8. Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

    MONT-SAINT-GUIBERT, Belgium, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today